Outcome
    Preliminary
    Effectiveness 3/5

    Indole-3-Carbinol for Estrogen Metabolism Support

    I3C reliably shifts estrogen metabolism toward 2-hydroxylation in human trials — a real, measurable effect whose long-term clinical meaning is still debated.

    Overview

    I3C reliably shifts estrogen metabolism toward 2-hydroxylation in human trials — a real, measurable effect whose long-term clinical meaning is still debated.

    Verdict

    Mixed evidence

    Biomarker effect proven; clinical outcomes less certain.

    How It Works

    In stomach acid, I3C condenses into DIM and related compounds that induce the liver enzyme CYP1A2. This shifts estradiol breakdown toward 2-hydroxyestrone and away from 16-alpha-hydroxyestrone, a ratio shift hypothesized to reduce overall estrogenic stimulation of breast and cervical tissue. It also modulates aryl hydrocarbon receptor signaling.

    Dosing & Protocol

    Typical dose

    Recommended dose
    200–400 mg daily with food
    Expected timeframe
    Ratio changes within 2–4 weeks; clinical outcomes over 12+ weeks

    Protocol

    form
    I3C converts to DIM and other condensation products in stomach acid, and that conversion is variable and pH-dependent - DIM is the more predictable option and is what many later studies used. Cruciferous vegetables supply I3C naturally
    duration
    12 weeks, with urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio measured at baseline and end if this is being taken seriously
    co factor
    Take with food. Evidence is mixed. I3C and DIM reliably shift oestrogen metabolism in humans: multiple studies show they increase the ratio of 2-hydroxyestrone to 16-alpha-hydroxyestrone in urine, by inducing CYP1A1-mediated 2-hydroxylation, and this is a reproducible biochemical effect. What is not established is that the shift matters. The hypothesis that a higher 2:16 ratio reduces breast cancer risk comes from observational data and is not confirmed by outcome trials, and I3C trials in cervical dysplasia and other endpoints have been small with inconsistent results. So the biomarker moves; the clinical significance is unproven.
    titration
    Up to 400 mg/day I3C or 200 mg/day DIM in divided doses
    starting dose
    200 mg/day I3C with a meal, or 100 mg/day DIM

    Evidence

    What the studies say

    Human trials confirm the metabolic shift: studies using 200–400 mg/day show significant increases in urinary 2:16 hydroxyestrone ratios within weeks. The strongest clinical data is a randomized placebo-controlled trial in cervical intraepithelial neoplasia, where about half of women on 200–400 mg/day had complete CIN regression versus none on placebo. Smaller studies support benefit in cyclic breast pain. However, whether favorably shifting the 2:16 ratio actually reduces long-term cancer risk is unproven, and pharmacological estrogen manipulation without medical oversight carries its own uncertainties.

    A phase I study of indole-3-carbinol in women: tolerability and effects on estrogen metabolism

    Score: 6/10
    2005
    rct
    n=20

    Reed GA, Peterson KS, Smith HJ +5 more

    Indole-3-carbinol was well tolerated up to 400 mg twice daily and increased the 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio.

    View source

    Indole-3-carbinol as a chemopreventive agent: mechanisms, clinical evidence and safety considerations

    Score: 6/10
    2010
    systematic_review
    0

    Ahmad A, Sakr WA, Rahman KM

    Human chemoprevention evidence remains limited to small biomarker studies.

    View source

    Safety

    Caveats

    A shifted oestrogen metabolite ratio is a biomarker, not a health outcome - do not treat it as cancer prevention. Any breast lump, nipple discharge, skin change or unexplained postmenopausal bleeding needs urgent medical assessment, and attending screening programmes matters far more than any supplement. Safety: I3C and DIM induce CYP1A2 and other cytochrome P450 enzymes, which can reduce levels of numerous medicines - this is a real and often overlooked interaction, affecting drugs including some antidepressants, antipsychotics, theophylline, tamoxifen metabolism and hormonal contraception. Discuss with a pharmacist before combining. High doses have caused nausea, and animal studies at very high doses raised concerns about tumour promotion in some models, so do not exceed the studied range. Avoid in pregnancy and breastfeeding, where safety is not established, and in children. Anyone with a hormone-sensitive cancer should only use these under oncology supervision. DIM commonly turns urine orange-brown, which is harmless.

    Less likely to help if

    People with normal oestrogen metabolism, in whom the biomarker shift has no demonstrated benefit.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.